Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445396 | 1.00 | REN (0.76) | REN | |
| SCHEMBL4439084 | 0.92 | REN (0.79) | REN | |
| SCHEMBL4439079 | 0.92 | REN (0.79) | REN | |
| SCHEMBL4437586 | 0.92 | REN (0.76) | REN | |
| SCHEMBL4437582 | 0.92 | REN (0.76) | REN | |
| SCHEMBL4438938 | 0.91 | REN (0.81) | REN | |
| SCHEMBL4438935 | 0.91 | REN (0.81) | REN | |
| SCHEMBL1596741 | 0.91 | REN (0.83) | REN | |
| SCHEMBL4438851 | 0.89 | REN (0.70) | REN | |
| SCHEMBL4438849 | 0.89 | REN (0.70) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615664-B2 | Phenyloctanamides | SPEEDEL EXPERIMENTA AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20080153902-A1 | E.g., 2 N-(2-Fluorophenyl)-5(S)-amino-4(S)-hydroxy-2(S)-isopropyl-7(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; renin inhibitors used for the treatment of hypertension, heart failure, glaucoma, myocardial infarction, kidney failure, restenoses or stroke | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| EP-1819663-B1 | OMEGA-PHENYLOCTANAMIDES | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1872780-A2 | Omega-Phenyloctanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153902-A1 | E.g., 2 N-(2-Fluorophenyl)-5(S)-amino-4(S)-hydroxy-2(S)-isopropyl-7(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; renin inhibitors used for the treatment of hypertension, heart failure, glaucoma, myocardial infarction, kidney failure, restenoses or stroke | REN, AGTR2, AGTR1 | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.